Novartis Reports Q2 2026 Earnings and Provides Full-Year Guidance
Novartis reported $14.4 billion in net sales for Q2 2026, a slight increase driven by growth from key products despite generic erosion. The company reaffirmed its full-year guidance with low single-digit revenue growth but expects core operating income to decline slightly.
Tickers: $NVS
Topics: financial_performance pharmaceuticals